Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery

RP Coll, SJ Bright, DKJ Martinus, DK Georgiou… - Molecular Imaging and …, 2023 - Springer
Critical advances in radionuclide therapy have led to encouraging new options for cancer
treatment through the pairing of clinically useful radiation-emitting radionuclides and …

Production of neutron deficient rare earth radionuclides by heavy ion activation

N Naskar, S Lahiri - Radiochimica Acta, 2022 - degruyter.com
The attempts to produce neutron deficient radioisotopes of rare Earth elements by heavy ion
activation are discussed in this review. The heavy ion induced reaction products have large …

Heavy-Ion Fusion Reaction Calculations: Establishing the Theoretical Frameworks for 111In Radionuclide over the Coupled Channel Model

ZM Cinan, B Erol, T Baskan, AH Yilmaz - Energies, 2021 - mdpi.com
In this work, the production of I 111 n radionuclide has been investigated theoretically via
heavy-ion fusion reactions of two stable nuclei: C 37 l+ G 74 e, M 26 g+ R 85 b, S 30 i+ B 81 …

Heavy-ion production of 77Br and 76Br

SR McGuinness, JT Wilkinson, GF Peaslee - Scientific reports, 2021 - nature.com
Many radioisotopes with potential medical applications are difficult to produce routinely,
especially those on the proton-rich side of the valley of stability. Current production methods …

[PDF][PDF] مﺮﺑ ﯽﮑﺷﺰﭘ ﺪﯿﺌﻠﮐﻮﻧﻮﯾدار ﺪﯿﻟﻮﺗ ﯽﺠﻨﺳ-76 ﻦﯿﮕﻨﺳ نﻮﯾ زا هدﺎﻔﺘﺳا ﺎﺑ Li 7

A Jamshidi, M Nirouei - sid.ir
Abstract Bromine-76 (half-life= 16.2 hours) is a positron emitter radionuclide with a high
potential for use in nuclear medicine; but due to the difficulty of producing commercial …